Norman Sharpless: Cautiously Optimistic about NIH and NCI Prospects Despite POTUS Budget Cut
Norman Sharpless, Managing Director at Jupiter Bioventures, shared a post on LinkedIn:
“As we await the Senate LHHS markup numbers for NIH and NCI, let me relay an observation I have been re-telling a lot in recent weeks. In my first year at NCI, POTUS’ budget had a 25% CUT to NCI, and Congress gave us a $300 million increase.
In my last year in the government, POTUS’ budget (‘Moonshot 2.0’) had a massive INCREASE, and Congress gave us a flat budget (essentially a CUT). So the R^2 between the POTUS budget and what Congress actually appropriates is very low.
I can’t help but feel that some of these academic institutions that are sharply cutting staff because of worries about future NIH funding are overreacting to the recent President’s budget (37% cut).
The POTUS budget is a political document, but I remain cautiously optimistic about NIH and NCI prospects because biomedical research (esp. cancer research) is very popular with Congress and the American public, and is an excellent use of federal funds. We’ll see what the Senate does soon…”
Jeff Molter, Health Communications Consultant at Jeff Molter Consulting, shared this post, adding:
“Let’s hope former National Cancer Institute (NCI) director Dr. Norman Sharpless’ optimistic view is what happens – that cancer research funding doesn’t get whacked too badly. ‘How can you be against cancer research?’ “
More posts featuring Norman Sharpless and Jeff Molter.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023